Adenoid Cystic Carcinoma of Lobar Bronchial Origin: 20-Year Experience at a Single Institution

Zhao, Ying; He, Guosheng; Zhai, Yirui; Zhou, Zongmei; Bi, Nan; Mao, Yousheng; Zhang, Yi; Xiao, Zefen; Gao, Shugeng; Lv, Jima; Xue, Qi; Feng, Qinfu

doi:10.1245/s10434-022-11590-5

Cited by 9 publications

(15 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Incomplete resection was identified by intraoperative frozen pathology, displaying the tumor's unstable invasion pattern, which resulted in a higher rate of positive surgical margins and consequently increased the risk of recurrence and metastasis 22,23 . In this study, a poorer prognosis was observed in the 23 patients who underwent R1 resection, which was in line with previous reports 24 . In certain cases, R1 resection surgery was performed to avoid extensive loss of trachea circular cartilage.…”

Section: Discussionsupporting

confidence: 85%

“…Chemotherapy remains one of the main treatment strategies for advanced PACC patients. The platinum‐based doublet regimen recommended by the NSCLC guidelines is considered the primary chemotherapy option for PACC, which includes carboplatin and cisplatin in combination with pemetrexed, as well as paclitaxel and gemcitabine 24 . Adjuvant radiotherapy is frequently recommended; however, its effectiveness has not been confirmed and there is a lack of consensus regarding its efficacy.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Primary pulmonary adenoid cystic carcinoma: A clinicopathological study of 64 patients

Tan,

Xu,

Shen

et al. 2023

Thoracic Cancer

View full text Add to dashboard Cite

BackgroundThis study aimed to investigate the clinicopathological features and prognostic indicators of primary pulmonary adenoid cystic carcinoma (PACC).MethodsClinical data were collected from 64 primary PACC patients and analyzed retrospectively at the Tianjin Medical University General Hospital, the West China Hospital of Sichuan University, the First Affiliated Hospital of Guangxi Medical University, and the Bishan Hospital of Chongqing Medical University from January 2003 to August 2023. The 64 patients (28 males and 36 females) were aged from 20 to 73 years, with a median age of 49 years and an average age of 49.3 years.ResultsImmunohistochemical staining showed that the tumors expressed CK7, S‐100 protein, CK5/6, CD117, and p63. Seven patients underwent fluorescence in situ hybridization (FISH) testing and three were found to have myeloblastosis (MYB) gene translocation. In total, 53 patients underwent surgery, among whom 31 received only surgery and 22 received both surgery and postoperative chemoradiotherapy. In addition, 10 patients received chemoradiotherapy only, while one patient underwent treatment with traditional Chinese medicine. The overall survival rates in the first, third, and fifth years were 98.4%, 95.3%, and 87.5%, respectively.ConclusionPrognostic analysis revealed that age, tumor size, lymph node metastasis status, margin status, and choice of treatment modality significantly influenced the patients' prognosis.

show abstract

Section: Discussionsupporting

confidence: 85%

Section: Discussionmentioning

confidence: 99%

Primary pulmonary adenoid cystic carcinoma: A clinicopathological study of 64 patients

Tan,

Xu,

Shen

et al. 2023

Thoracic Cancer

View full text Add to dashboard Cite

show abstract

“…Although progression-free survival of PACC patients treated with chemotherapy alone typically ranges from only 4 to 6 months (Ferrarotto et al, 2017; He & Chen, 2017; Huo et al, 2014), chemotherapy remains a primary treatment approach for advanced PACC patients. The platinum-containing dual-drug regimen recommended by the NSCLC guidelines, which includes carboplatin, cisplatin combined with pemetrexed, paclitaxel, and gemcitabine, is the mainstay chemotherapy regimen for PACC (Zhao et al, 2022). PACC patients often exhibit low or absent expression of PD-L1 (Wang et al, 2020), suggesting that immune checkpoint inhibitors alone might not be a beneficial treatment for PACC.…”

Section: Discussionmentioning

confidence: 99%

Renal Metastasis Arising From a Pulmonary Adenoid Cystic Carcinoma: A Rare Case Report and Literature Review

Ding,

Wang,

Liu

et al. 2024

Am J Mens Health

View full text Add to dashboard Cite

Adenoid cystic carcinoma (ACC), a rare malignancy, typically originates in salivary glands and is rarely found in other locations. In this case report, we describe a 54-year-old male patient who was presented to the Urology Department of Yantai Yuhuangding hospital with right-sided waist pain. The patient underwent percutaneous ultrasound-guided biopsies of lesions in the kidney and lung, which were histologically confirmed as primary adenoid cystic carcinoma of the lung and metastatic renal adenoid cystic carcinoma, respectively. Given the presence of multiple metastases, the patient received systemic palliative chemotherapy, which was well-tolerated and effectively controlled the tumor. At the last follow-up, there was no evidence of tumor progression in the patient.

show abstract

“…Therefore, it is easy to misdiagnose, leading to delay in treatment. The histology and biological behavior of PACC are similar to those of malignancies occurring in the salivary glands of the head and neck [ 14 ]. Thus, PACC is considered a low-grade slow-growing malignancy with a high incidence of peripheral nerve invasion and often shows a tendency to undergo submucosal extension [ 15 ].…”

Section: Epidemiological and Clinical Characteristicsmentioning

confidence: 99%

“…PACC is no capsule, medium hardness, and a median size of about 3–4 cm [ 14 ]. Lesions were also grayish white and the boundaries were unclear, and is mainly composed of ductal epithelial cells and mutated myoepithelial cells [ 23 ].…”

Section: Pathological and Immunohistochemical Examinationsmentioning

confidence: 99%

Pulmonary adenoid cystic carcinoma: molecular characteristics and literature review

et al. 2023

View full text Add to dashboard Cite

Background Pulmonary adenoid cystic carcinoma (PACC) is an exceptionally rare salivary gland-type malignant neoplasm. Because of its clinical manifestations, imaging features are not different from other types of non-small cell lung cancer, which is a diagnostic challenge for most doctors. Conclusions A review of the literature shows that high amounts of immunohistochemical (IHC) markers, such as CK7, CD117, P63, SMA, CK5/6, and S-100 are helpful for PACC diagnosis. Surgical resection is the main treatment of PACC, but treatment options for advanced PACC patients are limited and the research of molecular targeted drugs is ongoing in advanced cases not eligible for surgery. Currently, research on PACC targeted therapy mainly focuses on the exploration of v-myb avian myeloblastosis virus oncogene homolog (MYB) and its downstream target genes. In addition, median tumor mutation burden and PD-1/PD-L1 were lower in PACC, which may indicate poor efficacy of immunotherapy in PACC patients. This review focuses on the pathologic features, molecular characteristics, diagnosis, treatment and prognosis of PACC to establish a comprehensive understanding of PACC.

show abstract

Adenoid Cystic Carcinoma of Lobar Bronchial Origin: 20-Year Experience at a Single Institution

Cited by 9 publications

References 24 publications

Primary pulmonary adenoid cystic carcinoma: A clinicopathological study of 64 patients

Primary pulmonary adenoid cystic carcinoma: A clinicopathological study of 64 patients

Renal Metastasis Arising From a Pulmonary Adenoid Cystic Carcinoma: A Rare Case Report and Literature Review

Pulmonary adenoid cystic carcinoma: molecular characteristics and literature review

Contact Info

Product

Resources

About